Resverlogix is a biotechnology company that researches, develops and commercializes BET inhibitors for the treatment of chronic diseases.
Read moreAnnual Revenue
$3.2M
Resverlogix's revenue is the ranked 12th among it's top 10 competitors. The top 10 competitors average 67M. Over the last four quarters, Resverlogix's revenue has decreased by 72.9%. Specifically, in Q3 2014's revenue was $ < 1M; in Q2 2014, it was $ < 1M; in Q1 2014, it was $ < 1M; in Q4 2013, Resverlogix's revenue was $1.7M.